SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $356,785 | -20.9% | 24,572 | +14.1% | 0.00% | 0.0% |
| Q2 2023 | $450,790 | -8.1% | 21,538 | -7.3% | 0.00% | 0.0% |
| Q1 2023 | $490,575 | -23.4% | 23,228 | -7.7% | 0.00% | 0.0% |
| Q4 2022 | $640,704 | +21.6% | 25,175 | +14.8% | 0.00% | 0.0% |
| Q3 2022 | $527,000 | -22.5% | 21,929 | -38.0% | 0.00% | -50.0% |
| Q2 2022 | $680,000 | +64.6% | 35,358 | +48.9% | 0.00% | +100.0% |
| Q1 2022 | $413,000 | -1.2% | 23,751 | +27.1% | 0.00% | 0.0% |
| Q1 2021 | $418,000 | -37.2% | 18,680 | -37.7% | 0.00% | 0.0% |
| Q4 2020 | $666,000 | +5.0% | 29,963 | -30.2% | 0.00% | 0.0% |
| Q3 2020 | $634,000 | -4.5% | 42,935 | -4.2% | 0.00% | 0.0% |
| Q2 2020 | $664,000 | +462.7% | 44,808 | +317.6% | 0.00% | – |
| Q1 2020 | $118,000 | +59.5% | 10,729 | -24.0% | 0.00% | – |
| Q1 2019 | $74,000 | -67.5% | 14,117 | -45.8% | 0.00% | – |
| Q4 2017 | $228,000 | -41.2% | 26,068 | -21.5% | 0.00% | – |
| Q3 2017 | $388,000 | – | 33,189 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |